Efforts to improve surveillance in advance of the introduction of the Meningococcal Group C (conjugate) vaccination programme, led to the development in 1999 of MIDAS (Meningococcal Invasive Disease Augmented Surveillance, set up by SCIEH and SMPRL), which incorporates active case finding, vaccine status recording and improved follow up. The purpose of the enhanced surveillance set up was firstly to obtain baseline information on the Epidemiology of meningococcal disease in Scotland in order to assess the impact of the vaccination programme (post 1999) in terms of distribution by serogroup (the campaign being specific for group C) and age-band (the target group being all those aged under 20 years initially).
This surveillance system holds patient identifiable information.
By patient identifiable information we mean details such as name, address or
case record number. HPS seeks to limit to a minimum these details and many
systems are anonymised, e.g. do not hold individual names and addresses.
Should you wish details of the patient identifiable information held in this
system, please contact enquiries.